RecruitingPhase 3NCT05815927
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Panagiotis Belermpas, MDUniversity of Zurich
- Intervention
- Pembrolizumab(drug)
- Enrollment
- 200 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (26)
- Cliniques Universitaires Saint-Luc, Brussels, Belgium
- AZ Groeninge Kortrijk - Campus Kennedylaan, Kortrijk, Belgium
- CHU-UCL Namur - CHU Site Sainte-Elisabeth-UCL Namur, Namur, Belgium
- VITAZ St Niklaas - VITAZ- Oncology, Sint-Niklaas, Belgium
- Ziekenhuis aan de Stroom (ZAS) - ZAS Augustinus (previous GZA), Wilrijk, Belgium
- IRCCS--Ospedale Bellaria-Bologna, Bologna, Italy
- AUSL - Ospedale Infermi, Faenza, Italy
- Univ. of Florence -Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
- AUSL -Ospedale Umberto I, Lugo, Italy
- Istituto Clinico Humanitas, Milan, Italy
- IRCCS - Fondazione Istituto Nazionale dei Tumori, Milan, Italy
- Azienda Sanitaria Locale Napoli 1 Centro, Naples, Italy
- AUSL Romagna - AUSL Della Romagna -Ospedale Santa Maria delle Croci, Ravenna, Italy
- Azienda ospedaliero Univ Policlinico Umberto I, Rome, Italy
- Hospital Universitari Vall d'Hebron -Vall d'Hebron Institut Oncologia, Barcelona, Spain
- +11 more locations on ClinicalTrials.gov
Collaborators
Swiss Cancer Institute · Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05815927 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →